Status:
COMPLETED
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium
Lead Sponsor:
AstraZeneca
Conditions:
Adverse Events
Pharmacokinetic
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
To evaluate safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.
Eligibility Criteria
Inclusion
- General good health
- BMI 19 to 29
Exclusion
- Currently enrolled in another study
- Females who are pregnant or breastfeeding
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00681395
Start Date
May 1 2008
Last Update
September 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 8089
Orlando, Florida, United States, 32809